Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
about
Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic targetA study of nuclear transcription factor-kappa B in childhood autismThe NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemiaNF-κB addiction and its role in cancer: 'one size does not fit all'.NF-kappaB and cancer: how intimate is this relationshipNF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech populationSilvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells.Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells.Impact of C-rel inhibition of cord blood-derived B-, T-, and NK cells.NF-κB in Hematological Malignancies.
P2860
Q26995561-A1B35C48-0EF1-418B-8BD6-C770192E10BDQ28478093-E988A395-3684-48E0-8E8A-852DAA626BF0Q34176804-E6ABBF13-BCB9-4DA3-BD59-64764C3431E4Q35093305-4F4F0983-F99A-4105-9618-84F0EDF1A1C3Q35120893-FAC4DDE0-4D50-4239-B9A1-01FABF37CE05Q35143597-1F2AB456-E021-4D38-A280-C585996D3A55Q35814995-E27F6144-6787-4889-AA9D-20DBA9F4420CQ36565137-A45E0B26-35E3-4837-8E90-9FDD19043C29Q36758390-C264CD1D-21C0-43FD-B13C-2A05220A42BEQ37495206-B6AED67B-C585-4EA2-9E34-AA556B35FD9FQ37790694-E63C4DF7-7E2E-4F63-A17B-096A69928FC8Q39221664-D0FBC8C5-144F-47DA-8E10-CD4B44F7648FQ41219902-44154494-D2EA-42A1-AE8F-8501460C46E0Q47155915-812330BD-0275-4E6A-B3A9-311EE1977E99Q51043186-4554CD1B-0A8D-4CBA-8CE2-1ADBBB895BBCQ54147337-5D734935-1236-4D0B-A39C-41297CA066DA
P2860
Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Flt3 receptor inhibition reduc ...... me and acute myeloid leukemia.
@en
Flt3 receptor inhibition reduc ...... me and acute myeloid leukemia.
@nl
type
label
Flt3 receptor inhibition reduc ...... me and acute myeloid leukemia.
@en
Flt3 receptor inhibition reduc ...... me and acute myeloid leukemia.
@nl
prefLabel
Flt3 receptor inhibition reduc ...... me and acute myeloid leukemia.
@en
Flt3 receptor inhibition reduc ...... me and acute myeloid leukemia.
@nl
P2093
P50
P1433
P1476
Flt3 receptor inhibition reduc ...... me and acute myeloid leukemia.
@en
P2093
Alain Israel
Claire Fabre
Jennifer Grosjean-Raillard
Lionel Adès
Maximilien Tailler
Simone Boehrer
Thorsten Braun
P2888
P304
P356
10.1007/S10495-008-0243-4
P577
2008-09-01T00:00:00Z